Venture Life Group (LON:VLG) Trading Up 9.7% – Should You Buy?

Venture Life Group plc (LON:VLG) shares were up 9.7% during mid-day trading on Wednesday . The stock traded as high as GBX 62 and last traded at GBX 62. Approximately 195,728 shares changed hands during trading, a decline of 32% from the average daily volume of 288,004 shares. The stock had previously closed at GBX 56.50.

Venture Life Group Stock Up 8.8%

The firm has a 50 day moving average of GBX 61.35 and a two-hundred day moving average of GBX 64.09. The firm has a market capitalization of £74.92 million, a price-to-earnings ratio of 14.07, a price-to-earnings-growth ratio of 5.67 and a beta of 0.24. The company has a quick ratio of 1.48, a current ratio of 4.71 and a debt-to-equity ratio of 0.82.

Venture Life Group (LON:VLG) last released its quarterly earnings data on Tuesday, March 31st. The company reported GBX (1.49) earnings per share for the quarter. The business had revenue of GBX 3,517 million during the quarter. Venture Life Group had a net margin of 17.42% and a return on equity of 7.82%. As a group, sell-side analysts anticipate that Venture Life Group plc will post 6.1391542 EPS for the current fiscal year.

About Venture Life Group

Venture Life is an international consumer self-care company focused on developing and commercialising products for the global self-care market helping our consumers live a longer healthier and more rewarding life.

Headquartered in the UK, the Group’s product portfolio includes Balance Activ in the area of women’s intimate healthcare, Earol® supporting ENT care, Lift and Glucogel product ranges for energy and glucose management and hypoglycaemia, plus the Health & Her product range supporting the hormonal lifecycle.

The products, which are typically recommended by pharmacists or healthcare practitioners, are available primarily through health & beauty stores, pharmacies, grocery multiples and e-commerce channels and are sold globally.